Piperacillin-tazobactam/meropenem vs colistin/meropenem for carbapenem-resistant Klebsiella Pneumoniae-related ventilator-associated pneumonia
Abstract
Background: Ventilator-associated pneumonia (VAP) is a major concern in ICUs, particularly with carbapenem-resistant Klebsiella pneumoniae (CRKP). Dual beta-lactam antibiotic regimens may improve outcomes compared to traditional therapies. This study evaluates the efficacy and safety of meropenem/piperacillin-tazobactam versus meropenem/colistin for CRKP-related VAP. Primary outcomes are the change in Clinical Pulmonary Infection Score (CPIS) from baseline to Day 7, ICU length of stay, and ventilator-free days. Secondary outcomes include 28-day mortality, bacterial clearance, and renal or hepatic adverse events.
Methods: This randomized, open-label clinical trial will enroll 88 ICU patients with confirmed CRKP-related VAP. Participants will be randomly assigned to receive either meropenem/piperacillin-tazobactam or meropenem/colistin. The primary endpoints are improvement in CPIS, ICU length of stay, and ventilator-free days. Secondary endpoints include bacterial clearance and clinical recovery over 28 days. Safety will be assessed via renal and hepatic function monitoring and adverse event recording. Randomization and data collection follow SPIRIT 2013 guidelines to ensure rigor and transparency.
Discussion: Studies indicate that antibiotic combinations, particularly dual beta-lactam therapies, may enhance efficacy against resistant pathogens, including CRKP. While limited studies exist on dual beta-lactam regimens, recent findings suggest promising outcomes with…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 88 participants or records.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.